BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dai Z, Xu X, Ran Z. Associations Between Obesity and the Effectiveness of Anti–Tumor Necrosis Factor-α Agents in Inflammatory Bowel Disease Patients: A Literature Review and Meta-analysis. Ann Pharmacother 2020;54:729-41. [DOI: 10.1177/1060028019900660] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Chuck W, Shadbolt BF, Nordin F, Subramaniam K. BMI is important in predicting the loss of response in inflammatory bowel disease patients on tumour necrosis factor-α inhibitors. Eur J Gastroenterol Hepatol 2022;34:622-9. [PMID: 35352694 DOI: 10.1097/MEG.0000000000002371] [Reference Citation Analysis]
2 Juillerat P, Grueber MM, Ruetsch R, Santi G, Vuillèmoz M, Michetti P. Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom? Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100104] [Reference Citation Analysis]
3 Patsalos O, Dalton B, Leppanen J, Ibrahim MAA, Himmerich H. Impact of TNF-α Inhibitors on Body Weight and BMI: A Systematic Review and Meta-Analysis. Front Pharmacol 2020;11:481. [PMID: 32351392 DOI: 10.3389/fphar.2020.00481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
4 Mazhar F, Battini V, Pozzi M, Invernizzi E, Mosini G, Gringeri M, Capuano A, Scavone C, Radice S, Clementi E, Carnovale C. Changes in Anthropometric Parameters After Anti-TNFα Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. BioDrugs 2020;34:649-68. [PMID: 32940873 DOI: 10.1007/s40259-020-00444-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Johnson AM, Loftus EV. Obesity in inflammatory bowel disease: A review of its role in the pathogenesis, natural history, and treatment of IBD. Saudi J Gastroenterol 2021;27:183-90. [PMID: 34169900 DOI: 10.4103/sjg.sjg_30_21] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mazhar F, Battini V, Gringeri M, Pozzi M, Mosini G, Marran AMN, Akram S, van Manen RP, Radice S, Clementi E, Carnovale C. The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database. Expert Opin Biol Ther 2021;:1-10. [PMID: 34191656 DOI: 10.1080/14712598.2021.1948529] [Reference Citation Analysis]
7 Fitzpatrick JA, Melton SL, Yao CK, Gibson PR, Halmos EP. Dietary management of adults with IBD - the emerging role of dietary therapy. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35577903 DOI: 10.1038/s41575-022-00619-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ananthakrishnan AN, Kaplan GG, Bernstein CN, Burke KE, Lochhead PJ, Sasson AN, Agrawal M, Tiong JHT, Steinberg J, Kruis W, Steinwurz F, Ahuja V, Ng SC, Rubin DT, Colombel J, Gearry R, Abreu M, Ahuja V, Allez M, Ananthakrishnan A, Bemelman W, Bernstein C, Braun J, Chowers Y, Colombel J, Danese S, D'haens G, D'hoore A, Dignass A, Dotan I, Dubinsky M, Ekbom A, Fleshner P, Gasche C, Gassull M, Gearry R, Ghosh S, Gibson P, Griffiths A, Halfvarson J, Hanauer S, Harpaz N, Hart A, Hibi T, Kamm M, Kaplan G, Kaser A, Korelitz B, Kotze P, Koutroubakis I, Kruis W, Lakatos P, Lewis J, Lindsay J, Loftus E, Louis E, Lukas M, Magro F, Mahadevan U, Mantzaris G, Mary J, Mcgovern D, Moum B, Munkholm P, Neurath M, Ng S, O'morain C, Oresland T, Panaccione R, Panes J, Panis Y, Pemberton J, Peyrin-biroulet L, Prantera C, Rachmilewitz D, Ran Z, Reinisch W, Remzi F, Rhodes J, Riddell R, Rogler G, Rubin D, Sachar D, Sandborn W, Sands B, Sartor B, Schoelmerich J, Schreiber S, Siegel C, Siegmund B, Silverberg M, Söderholm J, Sood A, Spinelli A, Stange E, Steinwurz F, Targan S, Travis S, Turner D, Tysk C, Vatn M, Vermeire S, Watanabe M, Yamamoto T, Yamamoto-furusho J. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. The Lancet Gastroenterology & Hepatology 2022;7:666-78. [DOI: 10.1016/s2468-1253(22)00021-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hanzel J, Bukkems LH, Gecse KB, D'Haens GR, Mathôt RAA. Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2021;54:1309-19. [PMID: 34559426 DOI: 10.1111/apt.16609] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Gu P, Dube S, McGovern DPB. Medical and Surgical Implications of Mesenteric Adipose Tissue in Crohn's Disease: A Review of the Literature. Inflamm Bowel Dis 2022:izac120. [PMID: 35731568 DOI: 10.1093/ibd/izac120] [Reference Citation Analysis]
11 Allocca M, Danese S. Reply. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00574-7. [PMID: 34044130 DOI: 10.1016/j.cgh.2021.05.036] [Reference Citation Analysis]
12 Gu P, Chhabra A, Chittajallu P, Chang C, Mendez D, Gilman A, Fudman DI, Xi Y, Feagins LA. Visceral Adipose Tissue Volumetrics Inform Odds of Treatment Response and Risk of Subsequent Surgery in IBD Patients Starting Antitumor Necrosis Factor Therapy. Inflamm Bowel Dis 2021:izab167. [PMID: 34291800 DOI: 10.1093/ibd/izab167] [Reference Citation Analysis]